Duvyzat (givinostat) / Italfarmaco 
Welcome,         Profile    Billing    Logout  
 15 Diseases   5 Trials   5 Trials   208 News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Duvyzat (givinostat) / Italfarmaco
GIV-IN PV, NCT06093672: Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

Recruiting
3
220
Europe, US, RoW
Givinostat Hydrochloride, Hydroxy Urea
Italfarmaco
Polycythemia Vera
07/26
07/26
ULYSSES, NCT05933057: Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Recruiting
3
138
Europe, Canada
Givinostat, ITF2357, Placebo
Italfarmaco, Fortrea
Duchenne Muscular Dystrophy
02/28
02/28
NCT03373968 / 2017-000397-10: Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

Enrolling by invitation
2/3
206
Europe, Canada, US, RoW
Givinostat
Italfarmaco, Cromsource
Duchenne Muscular Dystrophy
12/25
12/25
2004-004854-19: A randomized, double-blind, placebo-controlled, parallel group multicenter study to investigate efficacy and safety of ITF 2357 in the management of patients with active moderate to severe Crohn’s disease

Ongoing
2
50
Europe
ITF2357, Capsule, hard
Italfarmaco S.p.A.
Crohn's disease
 
 
NCT01761968 / 2012-003499-37: Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

Active, not recruiting
2
90
Europe
givinostat, givinostat (ITF2357)
Italfarmaco
Chronic Myeloproliferative Neoplasms
12/26
12/26
NCT05860114: Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)

Completed
1
8
Europe
Givinostat, ITF2357
Italfarmaco
Drug Drug Interaction
05/22
05/22
NCT05845567: The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)

Completed
1
20
Europe
Givinostat, ITF2357, Clarithromycin, Klacid®
Italfarmaco
Drug Drug Interaction
05/22
05/22

Download Options